What You Should Know:
– Tandem Diabetes Care, an insulin delivery and diabetes technology company, has announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company’s Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).
– The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. This provides more flexibility in how people choose to manage their diabetes.
Clinical Validation and Ongoing Collaboration
The clearance for Lyumjev’s use with the t:slim X2 insulin pump and Control-IQ+ technology was based on data from a 13-week, multicenter study involving 179 individuals. This study demonstrated high satisfaction and quality of life benefits.
Tandem and Lilly collaborated to support the clinical trial demonstrating the benefits of using Lyumjev with Control-IQ+ technology. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump.
Availability/Pricing
The t:slim X2 pump is now cleared in the U.S. for use with Humalog, Novolog, and Lyumjev U-100 insulins. Lyumjev is available through the Lilly Insulin Value Program, which allows anyone with commercial insurance or no insurance to fill a monthly prescription for $35.
